MacroGenics Announces Presentations at ESMO 2021 Virtual Annual Congress
ROCKVILLE, MD, Sept. 12, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced poster presentations relating to multiple investigational product candidates at the European Society for Medical Oncology (ESMO) Virtual Conference, taking place September 16-21, 2021.
Posters will be available on September 16, 2021. Details are as follows:
620P - MGC018, an Anti-B7-H3 Antibody-Drug Conjugate (ADC), in Patients with Advanced Solid Tumors: Preliminary Results of Phase 1 Cohort Expansion
1379P - Margetuximab with Retifanlimab in HER2+, PD-L1+ First-Line Unresectable/Metastatic Gastroesophageal Adenocarcinoma (GEA): MAHOGANY Cohort A
627P - Phase 2 Neoadjuvant Trial of the Anti-B7-H3 Antibody, Enoblituzumab, in Men with Localized Prostate Cancer: Safety, Efficacy, and Immune Correlates
926TiP - Phae 2 Trial of Enoblituzumab Plus Retifanlimab or Tebotelimab in First-Line Treatment of Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Presentation Topic: Head and neck cancer, excluding thyroid
The abstracts referenced above were submitted to ESMO in May 2021 and are available on the ESMO website. The posters will be available for on-demand viewing on the ESMO website and on the "Events & Presentations" page in the Investor Relations section of MacroGenics' website at http://ir.macrogenics.com/events.cfm on or around September 16, 2021.
About MacroGenics, Inc.
Cautionary Note on Forward-Looking Statements
CONTACTS: Chris James, M.D., Vice President, Investor Relations & Corporate Communications Jim Karrels, Senior Vice President, CFO 1-301-251-5172, firstname.lastname@example.org
Face the Music: The New Age of Bluetooth
Smart Government â€“ Digital Signage and Citizen Kiosks
IoT Evolution #TECHSUPERSHOW Networking Live Party